Novartis pays US$ 310 million upfront to acquire anti-inflammatory drug player IFM Tre

By PharmaCompass

2019-04-04

Impressions: 96 Article

Swiss drug major Novartis has acquired a broad portfolio of immunomodulatory medicines through the acquisition of IFM Tre, a subsidiary of Boston, Massachusetts-based IFM Therapeutics LLC focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome. Immunomodulators are drugs that normalize the immune system.

The acquisition will give Novartis full rights to IFM Tre’s portfolio of anti-inflammatory therapies (NLPR3 antagonists), which consists of one clinical and two pre-clinical programs. IFM will receive US$ 310 million in upfront payments. It will also be eligible for up to US$ 1.265 billion in milestone payments, for a total of US$ 1.575 billion.

“IFM Tre’s compounds have demonstrated that they can fine-tune the immune system, offering a potentially potent approach for treating a large variety of diseases associated with inflammation,” Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), said in the statement.

The deal has already been approved by IFM’s board of directors and is expected to close in the second quarter of 2019.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass